Skip to Content
Merck
  • Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.

Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.

Bioorganic & medicinal chemistry (2010-02-23)
Yingjie Zhang, Jinhong Feng, Chunxi Liu, Lei Zhang, Jie Jiao, Hao Fang, Li Su, Xiaopan Zhang, Jian Zhang, Minyong Li, Binghe Wang, Wenfang Xu
ABSTRACT

Histone deacetylases (HDACs) are enzymes involved in tumor genesis and development. Herein, we report a novel series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as HDACs inhibitors. The preliminary biological screening showed that most of our compounds exhibited potent inhibitory activity against HDACs. Within this series, five compounds, 13a (IC(50)=0.58+/-0.10 microM), 7d (IC(50)=1.00+/-0.16 microM), 8l (IC(50)=1.06+/-0.14 microM), 7i (IC(50)=1.17+/-0.19 microM) and 7a (IC(50)=1.29+/-0.15 microM) possessed better HDACs inhibitory activity than Vorinostat (IC(50)=1.48+/-0.20 microM). So these five compounds could be used as novel lead compounds for further design of HDACs inhibitors. The anti-proliferative activities of a few compounds and the structure-activity relationships are also briefly discussed.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid hydrochloride, 96%
Sigma-Aldrich
(S)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid, 97%